The efficacy of BNT162b2 (Pfizer–BioNTech) and CoronaVac vaccines in patients with cancer

Although vaccination is efficacious and prevents infection in the general population, there is limited data about Coronavirus disease‐19 (Covid‐19) occurrence after vaccination in cancer patients. It was aimed to evaluate the efficacy of BNT162b2 (Pfizer–BioNTech) and CoronaVac vaccines against Covi...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medical virology 2022-09, Vol.94 (9), p.4138-4143
Main Authors: Simsek, Melih, Yasin, Ayse I., Besiroglu, Mehmet, Topcu, Atakan, Sucuoglu Isleyen, Zehra, Seker, Mesut, Turk, Haci Mehmet
Format: Article
Language:English
Subjects:
BNT162 Vaccine
Cancer
Cancer vaccines
Coronaviruses
COVID-19 - prevention & control
COVID-19 Vaccines
COVID‐19
Cross-Sectional Studies
Humans
Immunization
Neoplasms - complications
Patients
Polymerase chain reaction
Retrospective Studies
SARS‐CoV‐2
Severe acute respiratory syndrome
Statistical analysis
vaccination
Vaccines
Viral diseases
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although vaccination is efficacious and prevents infection in the general population, there is limited data about Coronavirus disease‐19 (Covid‐19) occurrence after vaccination in cancer patients. It was aimed to evaluate the efficacy of BNT162b2 (Pfizer–BioNTech) and CoronaVac vaccines against Covid‐19 in patients with cancer. In this single‐center, retrospective, cross‐sectional, and descriptive study, the data of cancer patients referred to the medical oncology clinic of a university hospital were analyzed. The sample of the study consisted of cancer patients who had Covid‐19 or were vaccinated against Covid‐19. A total number of 2578 patients were included in the study. Of the patients, 2000 have never been infected with severe acute respiratory syndrome coronavirus and 578 patients have had a positive reverse‐transcription polymerase chain reaction (RT‐PCR) for Covid‐19. It was found that 2094 patients (81.2%) were fully vaccinated, and 484 patients (18.8%) did not receive full‐dose vaccination. A statistically significant difference in Covid‐19 occurrence was found between the patients who had full‐dose vaccination or not (p = 0.000). In in‐group comparisons of full‐dose vaccinated patients, while no difference was observed between two doses of BNT162b2 (Pfizer–BioNTech) and three doses of CoronaVac (p = 0.432), a statistically significant difference was observed between all other groups (p 
ISSN:0146-6615
1096-9071
DOI:10.1002/jmv.27835